Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Kyongbo Pharmaceutical Co., Ltd. (214390) Stock Price & Analysis

214390 Stock Chart & Stats

₩5,130.00₩60.00(1.18%)
At close: 3:30 PM GMT+9
₩5.2K₩5.4K₩5.6KAug 10Aug 24Sep 7Sep 21Oct 6Oct 19Nov 2
Day’s Range
KRW 4,965.00 - KRW 5,140.00
52-Week Range
KRW 4,700.00 - KRW 9,300.00
Previous Close
KRW 5,070.00
Volume
N/A
Average Volume (3M)
15.52K
Market Cap
KRW 121.21B
Enterprise Value
KRW 267.53B
Total Cash (Recent Filing)
KRW 13.83B
Total Debt (Recent Filing)
KRW 158.00B
Price to Earnings (P/E)
114.8
Beta
0.06
Next Earnings
N/A
EPS Estimate
N/A
Last Dividend Ex-Date
Dec 29, 2025
Dividend Yield
0.97%

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Steady revenue expansion indicates improving demand and/or pricing across the company’s pharmaceutical business. Continued top-line growth can support operating leverage, fund product development, and strengthen commercialization scale over the next several quarters.

Gross Margin Improvement

The substantial gross-margin improvement shows that revenue growth is occurring with better product-level economics than in 2021. If retained, this provides greater capacity to absorb operating costs and convert future sales growth into stronger earnings.

Integrated Pharmaceutical Operations

Participation across pharmaceutical R&D, production, and commercialization gives Kyongbo an operating base spanning the product lifecycle. This breadth can support continuity from development through sales and provides several avenues for serving domestic and overseas healthcare markets.

Bears Say

Rising Leverage

Leverage has increased materially while equity remained relatively stable, leaving debt slightly above equity on a TTM basis. This reduces financial flexibility, raises dependence on external financing, and could constrain investment if profitability or cash generation weakens.

Persistent Negative Free Cash Flow

Repeatedly negative free cash flow means the business has not consistently self-funded its reinvestment or working-capital needs. Even with positive operating cash flow in most years, continued deficits can increase financing needs and weaken resilience over the next several quarters.

Thin And Volatile Profitability

Improved gross margins have not yet translated into durable bottom-line performance. Thin operating and net margins leave limited room for cost or demand pressure, while the sharp 2025 profit decline highlights earnings volatility and makes cash conversion harder to sustain.

Kyongbo Pharmaceutical Co., Ltd. News

214390 FAQ

What was Kyongbo Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Kyongbo Pharmaceutical Co., Ltd. lowest stock price was ₩4700.00 and its highest was ₩9300.00 in the past 12 months.
What is Kyongbo Pharmaceutical Co., Ltd.’s market cap?
Kyongbo Pharmaceutical Co., Ltd.’s market cap is ₩121.21B.
When is Kyongbo Pharmaceutical Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Kyongbo Pharmaceutical Co., Ltd.’s earnings last quarter?
Kyongbo Pharmaceutical Co., Ltd. released its earnings results on Nov 18, 2026. The company reported -₩36.266 earnings per share for the quarter.
Is Kyongbo Pharmaceutical Co., Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Kyongbo Pharmaceutical Co., Ltd. pay dividends?
Kyongbo Pharmaceutical Co., Ltd. pays a ― dividend of ₩50 which represents an annual dividend yield of 0.97%. See more information on Kyongbo Pharmaceutical Co., Ltd. dividends here
What is Kyongbo Pharmaceutical Co., Ltd.’s EPS estimate?
Kyongbo Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kyongbo Pharmaceutical Co., Ltd. have?
Kyongbo Pharmaceutical Co., Ltd. has 23,906,860 shares outstanding.
What happened to Kyongbo Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Kyongbo Pharmaceutical Co., Ltd. reported an EPS of -₩36.266 in its last earnings report. Following the earnings report the stock price went up 1.744%.
Which hedge fund is a major shareholder of Kyongbo Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in KR:214390
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology